MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7073
+0.0039
+0.55%
Opening 14:56 07/05 EDT
OPEN
0.7000
PREV CLOSE
0.7034
HIGH
0.7143
LOW
0.6500
VOLUME
106.86K
TURNOVER
44.60K
52 WEEK HIGH
2.420
52 WEEK LOW
0.6200
MARKET CAP
9.66M
P/E (TTM)
-0.7650
1D
5D
1M
3M
1Y
5Y
BRIEF-Phio Pharmaceuticals Presents Study Outline Of Its First Clinical Trial With Ph-762 For Advanced Melanoma At The 2022 Asco Annual Meeting
reuters.com · 06/06 18:16
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented a trial-in-progress poster descr...
PR Newswire · 06/06 18:15
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
Benzinga · 05/16 16:22
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/16 12:16
BRIEF-Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity Of HER2-CAR-T Cells At Asgct 2022
reuters.com · 05/16 12:05
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new preclinical data showing tha...
PR Newswire · 05/16 12:00
BRIEF-Phio Pharmaceuticals Reports Q1 2022 Results And Provides Business Update
reuters.com · 05/12 21:23
Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.11
Phio Pharmaceuticals press release (NASDAQ:PHIO): Q1 GAAP EPS of -$0.19 beats by $0.11. At March 31, 2022, the Company had cash of $20.5 million as compared with $24.1 million at
Seekingalpha · 05/12 20:52
More
No Data
Learn about the latest financial forecast of PHIO. Analyze the recent business situations of Phio Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PHIO stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
High6.00
Average6.00
Low6.00
Current 0.7073
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 21
Institutional Holdings: 1.31M
% Owned: 9.60%
Shares Outstanding: 13.66M
TypeInstitutionsShares
Increased
6
106.10K
New
1
1.00K
Decreased
6
214.47K
Sold Out
4
175.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.82%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Non-Executive Chairman/Independent Director
Robert Bitterman
President/Chief Executive Officer/Director
Geert Cauwenbergh
Independent Director
Patricia Bradford
Independent Director
H. Paul Dorman
Independent Director
Robert Ferrara
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data
No Data
About PHIO
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL-based therapeutics are used to strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT) and directly modify cells in the tumor microenvironment (the TME) to weaken a tumors defense. Its lead product candidate is PH-762, which is an INTASYL compound that activates immune cells to better recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1, a clinically validated target for immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression that impacts cell differentiation, and hence, cell function. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.